drugset / Trial / NCT04922658
Surufatinib or Surufatinib Combined With Vinorelbine for Non-Small Cell Lung Cancer
Phase 2
Active not recruiting
76 enrolled
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Non-randomizedParallel-groupOpen-labelTreatment
Summary
A phase II study to assess the efficacy and safety of Surufatinib or Surufatinib combined with Vinorelbine as third-line and posterior line treatment in patients with NSCLC
Timeline
- Start
- 2020-06-03
- Primary completion
- 2025-12-01
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Surufatinib | Small molecule | 250 mg | Oral |
| Subject | Surufatinib | Small molecule | 300 mg | Oral |
| Subject | Vinorelbine | Small molecule | 20 mg | Oral |